ML20137Z530

From kanterella
Jump to navigation Jump to search
Amend 7 to License 50-19913-01 for Ketchikan General Hosp, Modifying Condition 12 Re Authorized Users
ML20137Z530
Person / Time
Site: 03019521
Issue date: 09/04/1985
From: Thomas R
NRC OFFICE OF INSPECTION & ENFORCEMENT (IE REGION V)
To:
Shared Package
ML20137Z535 List:
References
50-19913-01, 50-19913-1, NUDOCS 8510080266
Download: ML20137Z530 (1)


See also: IR 05000199/2013001

Text

manmTmawarmmmwrrawarainm ainsmanwaram;rrirmrErswrystrictgaw.mApa_# m

-

RC Forrn 374A

U.S. NUCLEAR REGULATORY COMMISSION l

1

1

h

p

gp

PAGES

License number

'

.

50-19913-01

!

. MATERIALS LICENSE

@

nocket or Reference number

t

SUPPLEMEN1 ARY SHEET

030-19521

i

,

_ _ _ . _ _

-,

t

Amendment No. 7

l

!

.

!

',

!i Ketchikan General Hospital

i

l

3100 Tongass Avenue

I

! Ketchikan, Alaska 99901

l

,

l

j

In accordance with telegram dated September 4, 1985 from Sister Barbara Haase,

.

l Administrator, License Number 50-19913-01 is amended as follows:

1

-

License Condition 12. is amended to read:

1

i

!

12.

Licensed material listed in Item 6 jbovekis authorized for use by, or under the

i

supervision of, the following. individuals forthe ? materials and uses indicated:

!

~ . - '

.

_

.

I

Stuart A. O'Byrne, M.DJ

- '

Groups I, II, and'III

In vitro studies

!

- '

,

l

Enon 133

%

{p!

l

!

Phosphorus 32 as soluble phosphate for

j

treatment of polycythemia vera,

,

~

'

'

!

leukemia',?and bone metastases

.

'

l

j.

, ;-

L. .

r

,

,

Donald Klein, M.D.

-

~ Groups I,111, and III('-

'

l

In' vitro studies

_

r

-

Xenon,133~

'

'

'

"

Phosphorus 32'as soluble' phosphate for

.

l

- j "

-

treatment 'of ' polycythemia vera,

' ~

- i / leukemia, and bone idetastases

!

'

- k

'

!

<

,

Groups I;. U , and II 6

" ' '

Louise Isenberg-Dallaire, M.D. .

l

D

,

In vitro; studies

3

8

l>

.

l Xenon 133"

.rs

,

-

,b

,

-

John C. Jowett, M.D.

Groups I, II,N_and III

'

i

,.

g!

M vitro' studies

I

d

,

, Xenon 133'

N

-

.,

.

!

g

1

j

Rush A. Youngberg, M.D.

Groups I, II, and III

i

! l

l

In vitro

}

j!

Xenon 133

l

g

Phosphorus 32 as soluble phosphate for

i

ll

treatment of polycythemia vera,

I

I!

leukemia, and bone metastases

!

ll

'

I!

!

I'

I

'

'

gl

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

l

i

g;

!-

l

Il

SEP 4

1985

f'.;~'pp "

g

i

Date

By

' ' '" '

f)

'

I

l

R. D. Thomas, Chief

l

Nuclear Materials Safety Section

g

Region V

!p

81% hBM*

ll

I

ll

ppg

\\

lp

R $$9913-0i

hk @ \\

__m..___

_

- , _ _ _ ___j

g

_____m

- . . _

_

.._ _..___ _

.

, _ . , _ _ _ _ , _ . . _ _ _ _ _ _ _ _ , _ _ _ _ _ _ _ _ _ _ . _ _

_ _ _

. - _ _ _ _ _ . , _